Therefore, we conclude that further investigation into the role of NK-specific metabolic processes and tumor expression of TLR4 and STMN1 is indicated to increase understanding of the genes that drive immune cell infiltration into STS and how expression of these genes can be targeted to improve immunotherapy responses in STS. The gene discussed is TLR4; the disease is telomere syndrome.